OBJECTIVE: To assess the association of early proton magnetic resonance spectroscopy (¹H-MRS) metabolite ratios with adverse outcomes at 5-8 years in infants with hypoxic-ischaemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH) and to compare the association with outcome at 5-8 years versus outcome at 2 years. DESIGN, SETTING AND PATIENTS: Single-centre, retrospective cohort study of 91 infants with moderate to severe HIE undergoing TH between 2011 and 2020, ¹H-MRS performed between day 4 and 6 after birth and outcome at 5-8 years. The subgroup with both 2-year and 5-year to 8-year outcomes (n=81) was used for comparative analyses. Adverse outcome at 5-8 years was defined as death or moderate-severe disability (total intelligence quotient score <85, Movement Assessment Battery for Children II <15th percentile, cerebral palsy and severe sensory impairment). RESULTS: Among 91 infants, 49 (54%) had adverse outcomes at 5-8 years, including 20 who died. The lactate/N-acetylaspartate (Lac/NAA) peak-area ratio was the strongest predictor of adverse outcome at school age (area under the curve (AUC) of 0.90 and OR 1.11 per 0.01 increase (95% CI 1.05 to 1.16)).The predictive performance of neonatal ¹H-MRS was slightly higher at 2 years, with Lac/NAA AUC 0.93 (OR 1.11, 95% CI 1.05 to 1.16) versus 0.89 (OR 1.09, 95% CI 1.04 to 1.15) at 5-8 years, with comparable effect sizes indicating preserved long-term association. CONCLUSIONS: Neonatal ¹H-MRS biomarkers, especially Lac/NAA peak-area ratio, were associated with adverse outcomes at school age. Including ¹H-MRS in routine neonatal imaging could improve prognostication and guide early interventions.
No takes yet. Share an insight, caveat, or question.
Vicente et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: